Hansoh Pharmaceutical Group Co Ltd
3KY
Company Profile
Business description
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Contact
287 Xiangke Road
Pudong New District
Shanghai201210
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
8,989
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,816.40 | 58.90 | -0.66% |
| CAC 40 | 7,774.85 | 8.64 | 0.11% |
| DAX 40 | 24,200.10 | 139.81 | 0.58% |
| Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
| FTSE 100 | 8,971.03 | 32.71 | 0.37% |
| HKSE | 24,517.76 | 72.36 | -0.29% |
| NASDAQ | 20,677.80 | 37.47 | 0.18% |
| Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
| NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
| S&P 500 | 6,243.76 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
| SSE Composite Index | 3,503.78 | 1.22 | -0.03% |